However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...

Purpose. The clinical and economic benefits of aromatase inhibitor (AI) therapy in early-stage breast cancer are reviewed. Summary. AI therapy has become a standard of care for the treatment of most ...

Celcuity ( (CELC)) just unveiled an announcement. On May 1, 2026, Celcuity announced positive topline Phase 3 VIKTORIA-1 results in patients with PIK3CA mutant HR+/HER2- advanced or metastatic breast ...

A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Learn Look Locate (LLL), a global leader in breast cancer education and patient support, is proud to announce the launch of a groundbreaking new educational webpage on aromatase inhibitors in ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

Dear Dr. Roach: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.